Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer

A phase I/II trial

Silvia C. Formenti, Matthew Volm, Kristin A. Skinner, Darcy Spicer, Deidre Cohen, Edith Perez, Anna C. Bettini, Susan Groshen, Conway Gee, Barbara Florentine, Michael Press, Peter Danenberg, Franco Muggia

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Purpose: Preoperative chemotherapy is the conventional primary treatment in locally advanced breast cancer (LABC). We investigated the safety and efficacy of primary twice-weekly paclitaxel and concurrent radiation (RT) before modified radical mastectomy followed by adjuvant doxorubicin-based chemotherapy. Patients and Methods: Stage IIB (T3N0) to III LABC patients were eligible. Primary chemoradiation consisted of paclitaxel, 30 mg/m2 delivered intravenously for 1 hour twice weekly for a total of 8 to 10 weeks, and concurrent RT (45 Gy at 1.8 Gy/fraction). Modified radical mastectomy was performed at least 2 weeks after completion of chemoradiation or on recovery of skin toxicity. Postoperatively, patients who responded to paclitaxel and RT received four cycles of doxorubicin/paclitaxel, whereas patients who did not respond received doxorubicin/cytoxan. Results: Forty-four patients were accrued. Toxicity from paclitaxel/RT included grade 3 skin desquamation (7%), hypersensitivity (2%), and stomatitis (2%). Postsurgery complications occurred in six patients (14%). The only grade 4 toxicity of postmastectomy chemotherapy was hematologic (10%). Grade 3 toxicities were leukopenia (24%), infection (22%), peripheral neuropathy (17%), arthralgia and pain (17%), stomatitis (12%), fatigue (10%), esophagitis (5%), and nausea (2%). Overall clinical response rate to preoperative paclitaxel and RT was 91%. Thirty-four percent of patients achieved a pathologic response in the mastectomy specimen: 16% pathologic complete responses (clearance of invasive cancer in the breast and axillary contents) and 18% pathologic partial responses (< 10 residual microscopic foci of invasive breast cancer). Conclusion: Twice-weekly paclitaxel with concurrent RT is a feasible and effective primary treatment for LABC. Future studies should compare primary chemoradiation to chemotherapy in LABC.

Original languageEnglish (US)
Pages (from-to)864-870
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number5
DOIs
StatePublished - Mar 1 2003

Fingerprint

Paclitaxel
Doxorubicin
Radiotherapy
Breast Neoplasms
Drug Therapy
Radiation
Modified Radical Mastectomy
Stomatitis
Radiation Dosage
Skin
Esophagitis
Mastectomy
Leukopenia
Arthralgia
Peripheral Nervous System Diseases
Cyclophosphamide
Nausea
Fatigue
Hypersensitivity
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer : A phase I/II trial. / Formenti, Silvia C.; Volm, Matthew; Skinner, Kristin A.; Spicer, Darcy; Cohen, Deidre; Perez, Edith; Bettini, Anna C.; Groshen, Susan; Gee, Conway; Florentine, Barbara; Press, Michael; Danenberg, Peter; Muggia, Franco.

In: Journal of Clinical Oncology, Vol. 21, No. 5, 01.03.2003, p. 864-870.

Research output: Contribution to journalArticle

Formenti, SC, Volm, M, Skinner, KA, Spicer, D, Cohen, D, Perez, E, Bettini, AC, Groshen, S, Gee, C, Florentine, B, Press, M, Danenberg, P & Muggia, F 2003, 'Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: A phase I/II trial', Journal of Clinical Oncology, vol. 21, no. 5, pp. 864-870. https://doi.org/10.1200/JCO.2003.06.132
Formenti, Silvia C. ; Volm, Matthew ; Skinner, Kristin A. ; Spicer, Darcy ; Cohen, Deidre ; Perez, Edith ; Bettini, Anna C. ; Groshen, Susan ; Gee, Conway ; Florentine, Barbara ; Press, Michael ; Danenberg, Peter ; Muggia, Franco. / Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer : A phase I/II trial. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 5. pp. 864-870.
@article{d6cc666cee79487f996f5a08a2b4bc18,
title = "Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: A phase I/II trial",
abstract = "Purpose: Preoperative chemotherapy is the conventional primary treatment in locally advanced breast cancer (LABC). We investigated the safety and efficacy of primary twice-weekly paclitaxel and concurrent radiation (RT) before modified radical mastectomy followed by adjuvant doxorubicin-based chemotherapy. Patients and Methods: Stage IIB (T3N0) to III LABC patients were eligible. Primary chemoradiation consisted of paclitaxel, 30 mg/m2 delivered intravenously for 1 hour twice weekly for a total of 8 to 10 weeks, and concurrent RT (45 Gy at 1.8 Gy/fraction). Modified radical mastectomy was performed at least 2 weeks after completion of chemoradiation or on recovery of skin toxicity. Postoperatively, patients who responded to paclitaxel and RT received four cycles of doxorubicin/paclitaxel, whereas patients who did not respond received doxorubicin/cytoxan. Results: Forty-four patients were accrued. Toxicity from paclitaxel/RT included grade 3 skin desquamation (7{\%}), hypersensitivity (2{\%}), and stomatitis (2{\%}). Postsurgery complications occurred in six patients (14{\%}). The only grade 4 toxicity of postmastectomy chemotherapy was hematologic (10{\%}). Grade 3 toxicities were leukopenia (24{\%}), infection (22{\%}), peripheral neuropathy (17{\%}), arthralgia and pain (17{\%}), stomatitis (12{\%}), fatigue (10{\%}), esophagitis (5{\%}), and nausea (2{\%}). Overall clinical response rate to preoperative paclitaxel and RT was 91{\%}. Thirty-four percent of patients achieved a pathologic response in the mastectomy specimen: 16{\%} pathologic complete responses (clearance of invasive cancer in the breast and axillary contents) and 18{\%} pathologic partial responses (< 10 residual microscopic foci of invasive breast cancer). Conclusion: Twice-weekly paclitaxel with concurrent RT is a feasible and effective primary treatment for LABC. Future studies should compare primary chemoradiation to chemotherapy in LABC.",
author = "Formenti, {Silvia C.} and Matthew Volm and Skinner, {Kristin A.} and Darcy Spicer and Deidre Cohen and Edith Perez and Bettini, {Anna C.} and Susan Groshen and Conway Gee and Barbara Florentine and Michael Press and Peter Danenberg and Franco Muggia",
year = "2003",
month = "3",
day = "1",
doi = "10.1200/JCO.2003.06.132",
language = "English (US)",
volume = "21",
pages = "864--870",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer

T2 - A phase I/II trial

AU - Formenti, Silvia C.

AU - Volm, Matthew

AU - Skinner, Kristin A.

AU - Spicer, Darcy

AU - Cohen, Deidre

AU - Perez, Edith

AU - Bettini, Anna C.

AU - Groshen, Susan

AU - Gee, Conway

AU - Florentine, Barbara

AU - Press, Michael

AU - Danenberg, Peter

AU - Muggia, Franco

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Purpose: Preoperative chemotherapy is the conventional primary treatment in locally advanced breast cancer (LABC). We investigated the safety and efficacy of primary twice-weekly paclitaxel and concurrent radiation (RT) before modified radical mastectomy followed by adjuvant doxorubicin-based chemotherapy. Patients and Methods: Stage IIB (T3N0) to III LABC patients were eligible. Primary chemoradiation consisted of paclitaxel, 30 mg/m2 delivered intravenously for 1 hour twice weekly for a total of 8 to 10 weeks, and concurrent RT (45 Gy at 1.8 Gy/fraction). Modified radical mastectomy was performed at least 2 weeks after completion of chemoradiation or on recovery of skin toxicity. Postoperatively, patients who responded to paclitaxel and RT received four cycles of doxorubicin/paclitaxel, whereas patients who did not respond received doxorubicin/cytoxan. Results: Forty-four patients were accrued. Toxicity from paclitaxel/RT included grade 3 skin desquamation (7%), hypersensitivity (2%), and stomatitis (2%). Postsurgery complications occurred in six patients (14%). The only grade 4 toxicity of postmastectomy chemotherapy was hematologic (10%). Grade 3 toxicities were leukopenia (24%), infection (22%), peripheral neuropathy (17%), arthralgia and pain (17%), stomatitis (12%), fatigue (10%), esophagitis (5%), and nausea (2%). Overall clinical response rate to preoperative paclitaxel and RT was 91%. Thirty-four percent of patients achieved a pathologic response in the mastectomy specimen: 16% pathologic complete responses (clearance of invasive cancer in the breast and axillary contents) and 18% pathologic partial responses (< 10 residual microscopic foci of invasive breast cancer). Conclusion: Twice-weekly paclitaxel with concurrent RT is a feasible and effective primary treatment for LABC. Future studies should compare primary chemoradiation to chemotherapy in LABC.

AB - Purpose: Preoperative chemotherapy is the conventional primary treatment in locally advanced breast cancer (LABC). We investigated the safety and efficacy of primary twice-weekly paclitaxel and concurrent radiation (RT) before modified radical mastectomy followed by adjuvant doxorubicin-based chemotherapy. Patients and Methods: Stage IIB (T3N0) to III LABC patients were eligible. Primary chemoradiation consisted of paclitaxel, 30 mg/m2 delivered intravenously for 1 hour twice weekly for a total of 8 to 10 weeks, and concurrent RT (45 Gy at 1.8 Gy/fraction). Modified radical mastectomy was performed at least 2 weeks after completion of chemoradiation or on recovery of skin toxicity. Postoperatively, patients who responded to paclitaxel and RT received four cycles of doxorubicin/paclitaxel, whereas patients who did not respond received doxorubicin/cytoxan. Results: Forty-four patients were accrued. Toxicity from paclitaxel/RT included grade 3 skin desquamation (7%), hypersensitivity (2%), and stomatitis (2%). Postsurgery complications occurred in six patients (14%). The only grade 4 toxicity of postmastectomy chemotherapy was hematologic (10%). Grade 3 toxicities were leukopenia (24%), infection (22%), peripheral neuropathy (17%), arthralgia and pain (17%), stomatitis (12%), fatigue (10%), esophagitis (5%), and nausea (2%). Overall clinical response rate to preoperative paclitaxel and RT was 91%. Thirty-four percent of patients achieved a pathologic response in the mastectomy specimen: 16% pathologic complete responses (clearance of invasive cancer in the breast and axillary contents) and 18% pathologic partial responses (< 10 residual microscopic foci of invasive breast cancer). Conclusion: Twice-weekly paclitaxel with concurrent RT is a feasible and effective primary treatment for LABC. Future studies should compare primary chemoradiation to chemotherapy in LABC.

UR - http://www.scopus.com/inward/record.url?scp=0037364373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037364373&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.06.132

DO - 10.1200/JCO.2003.06.132

M3 - Article

VL - 21

SP - 864

EP - 870

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -